|
|
|
|
Stretching Improves Shoulder Contracture, Arm Pain in Kids Who Play Baseball
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Stretching Improves Shoulder Contracture, Arm Pain in Kids Who Play Baseball
_ Stretching Improves Shoulder Contracture, Arm Pain in Kids Who Play Baseball.
|
|
|
Auxilium Announces Availability Of XIAFLEXTM For The Treatment Of Dupuytren's Contracture
Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, announced that XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, is now available by prescription in the United States...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of Xiaflex for the Treatment of Dupuytren's Contracture
LYNBROOK, N.Y., March 8 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp.( NASDAQ:BSTC) , a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX(TM) is now available in the U.S. by...
|
|
|
Medical News: Auxilium Announces Availability Of XIAFLEXTM For The Treatment Of Dupuytren's Contracture
Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, announced that XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, is now available by prescription in the United States...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
LYNBROOK, N.Y., March 8 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription,...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
|
|
BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
BioSpecifics Technologies Corp.(Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture...
|
